NCT06923475 - Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

November 6, 2028

Study Completion Date

November 6, 2028

Conditions

Extrahepatic CholangiocarcinomaPerihilar CholangiocarcinomaDistal CholangiocarcinomaResectableBorderline Resectable

Interventions

DRUG

Pembrolizumab

Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)

DRUG

Gemcitabine, Cisplatin

Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)

Trial Locations (1)

Unknown

Amsterdam University Medical Center, Amsterdam